Published in Expert Opin Drug Metab Toxicol on February 19, 2014
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med (2008) 25.70
Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med (2010) 8.69
Hypoglycemia in diabetes. Diabetes Care (2003) 6.19
Autonomic contribution to blood pressure and metabolism in obesity. Hypertension (2006) 2.25
Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care (2010) 1.71
The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. J Diabetes Complications (2011) 1.29
Effects of low and moderate antecedent exercise on counterregulatory responses to subsequent hypoglycemia in type 1 diabetes. Diabetes (2004) 1.20
A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf (2012) 1.17
Exercise-related hypoglycemia in diabetes mellitus. Expert Rev Endocrinol Metab (2011) 1.11
Acute, same-day effects of antecedent exercise on counterregulatory responses to subsequent hypoglycemia in type 1 diabetes mellitus. Am J Physiol Endocrinol Metab (2006) 1.05
Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care (2011) 1.04
Leptin: metabolic control and regulation. J Diabetes Complications (2003) 1.03
Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes. Diabetes (2008) 1.03
Effect of antecedent hypoglycemia on counterregulatory responses to subsequent euglycemic exercise in type 1 diabetes. Diabetes (2003) 1.01
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs (2014) 1.00
Effects of a selective serotonin reuptake inhibitor, fluoxetine, on counterregulatory responses to hypoglycemia in healthy individuals. Diabetes (2008) 0.98
Estrogen blunts neuroendocrine and metabolic responses to hypoglycemia. Diabetes (2003) 0.98
Overcoming psychological barriers to insulin use in type 2 diabetes. Clin Cornerstone (2006) 0.93
The renin-angiotensin-aldosterone system: a pivotal role in insulin sensitivity and glycemic control. Curr Opin Endocrinol Diabetes Obes (2008) 0.90
Glucoregulation during and after exercise in health and insulin-dependent diabetes. Exerc Sport Sci Rev (2005) 0.89
Cortisol acts through central mechanisms to blunt counterregulatory responses to hypoglycemia in conscious rats. Diabetes (2003) 0.89
Hypoglycemia associated autonomic failure. Clin Auton Res (2002) 0.88
Brain region-dependent effects of dexamethasone on counterregulatory responses to hypoglycemia in conscious rats. Am J Physiol Regul Integr Comp Physiol (2004) 0.87
An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications? Curr Diabetes Rev (2013) 0.87
Effects of antecedent GABAA activation with alprazolam on counterregulatory responses to hypoglycemia in healthy humans. Diabetes (2010) 0.86
Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother (2011) 0.86
Effect of differing antecedent hypoglycemia on counterregulatory responses to exercise in type 1 diabetes. Am J Physiol Endocrinol Metab (2006) 0.85
Dose-response effects of insulin glargine in type 2 diabetes. Diabetes Care (2010) 0.85
Effects of differing antecedent increases of plasma cortisol on counterregulatory responses during subsequent exercise in type 1 diabetes. Diabetes (2009) 0.85
Effect of gender on counterregulatory responses to euglycemic exercise in type 1 diabetes. J Clin Endocrinol Metab (2002) 0.84
Effect of sex on counterregulatory responses to exercise after antecedent hypoglycemia in type 1 diabetes. Am J Physiol Endocrinol Metab (2004) 0.84
Effects of oral carbohydrate on autonomic nervous system counterregulatory responses during hyperinsulinemic hypoglycemia and euglycemia. Am J Physiol Endocrinol Metab (2008) 0.84
Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. J Diabetes Complications (2007) 0.84
Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol (2015) 0.84
Differing physiological effects of epinephrine in type 1 diabetes and nondiabetic humans. Am J Physiol Endocrinol Metab (2005) 0.83
Antecedent short-term central nervous system administration of estrogen and progesterone alters counterregulatory responses to hypoglycemia in conscious male rats. Am J Physiol Endocrinol Metab (2007) 0.83
Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol (2013) 0.82
NO synthase inhibition increases aldosterone in humans. Hypertension (2004) 0.82
Basal insulin treatment in type 2 diabetes. Diabetes Technol Ther (2011) 0.82
Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. Expert Opin Drug Metab Toxicol (2011) 0.82
The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol (2010) 0.82
Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study. Diabetes Technol Ther (2012) 0.81
The effects of dehydroepiandrosterone sulfate on counterregulatory responses during repeated hypoglycemia in conscious normal rats. Diabetes (2004) 0.80
Combination of glibenclamide-metformin HCl for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother (2012) 0.79
Effects of glycemic control on target organ responses to epinephrine in type 1 diabetes. Am J Physiol Endocrinol Metab (2005) 0.79
Physical activity in adolescents with type 1 diabetes: is more better for glycemic control? Pediatr Diabetes (2009) 0.78
Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment. Curr Diab Rep (2008) 0.78
Caffeine: a cause of insulin resistance? Diabetes Care (2002) 0.78
Stimulation of both type I and type II corticosteroid receptors blunts counterregulatory responses to subsequent hypoglycemia in healthy man. Am J Physiol Endocrinol Metab (2008) 0.77
Hypoglycemia and vascular disease. Clin Chem (2010) 0.76
Optimizing combination therapy for type 2 diabetes in adolescents and adults: a case-based approach. J Fam Pract (2004) 0.76
New concepts in diabetes: how multihormonal regulation can improve glycemic control. J Manag Care Pharm (2004) 0.76
Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol (2012) 0.76
Metabolic consequences of exercise-associated autonomic failure. Exerc Sport Sci Rev (2006) 0.76
Diabetes: Hypoglycemia-a new approach to an old problem. Nat Rev Endocrinol (2009) 0.76
Prior exercise and the response to insulin-induced hypoglycemia in the dog. Am J Physiol Endocrinol Metab (2002) 0.75
The cardiovascular effects of insulin. Expert Opin Drug Saf (2014) 0.75
Forebrain and hindbrain effects of ethanol on counterregulatory responses to hypoglycemia in conscious rats. Metabolism (2007) 0.75
Discontinued in 2013: diabetic drugs. Expert Opin Investig Drugs (2014) 0.75
The endocannabinoid system as a target for obesity treatment. Clin Cornerstone (2008) 0.75
Leptin responses to antecedent exercise and hypoglycemia in healthy and type 1 diabetes mellitus men and women. J Diabetes Complications (2003) 0.75
Early intervention to achieve optimal outcomes in type 2 diabetes: a case presentation. Clin Cornerstone (2006) 0.75